Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial The effect of curcumin on lipid level in patients with acute coronary syndrome. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial Curcumin effects on blood lipid profile in a 6-month human study. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Impact of polyunsaturated vegetable oils on adiponectin levels, glycaemia and blood lipids in individuals with type 2 diabetes: a randomised, double-blind intervention study. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Efficacy of Turmeric as Adjuvant Therapy in Type 2 Diabetic Patients Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial.
This study aim ed to assess the possible beneficial effects of curcumin capsules as lipid-lowering effects and as a permeability glycoprotein ( P-gp ) inhibitor on the pharmacokinetics and pharmacodynamics of glyburide and as a P-gp substrate with glyburide in patients with type-2 diabetes mellitus . Open-label , r and omized control trial was carried out for 11 days on eight type-2 diabetic patients on glyburide therapy .  On the first day of the study , following the administration of 5 mg of glyburide , blood sample s were collected from the patients at various time intervals ranging from 0.5 to 24 h. Blood sampling was repeated on the 11th day of the study , after treating the patients with curcumin for ten consecutive days . Glyburide concentrations changed at the second hour , Cmax was unchanged , the glucose levels were decreased , Area Under first Movement Curre ( AUMC ) was increased , and no patient has experienced the hypoglycaemia . The low-density lipoprotein , very-low-density lipoprotein and triglycerides were decreased significantly , and the high-density lipoprotein content increased . The co-administration of curcumin capsules with glyburide may be beneficial to the patients in better glycaemic control . The lipid lowering and antidiabetic properties of the curcumin show as a potential future drug molecule Objective : Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia result ing from defects in insulin secretion , insulin action , or both or insulin resistance . Curcumin inhibits NF-κB signaling pathway . The aim of this study is evaluation of the effect of Nano-curcumin on HbA1C , fast blood glucose and lipid profile in diabetic patients . Material s and Methods : Seventy type-2 diabetic patients ( fasting blood glucose ( FBG ) ≥ 126 mg/dL or 2-hr postpr and ial blood glucose ≥200 mg/dl ) r and omly receivedeither Curcumin ( as nano-micelle 80 mg/day ) or placebo  for 3 months in a double blind r and omized clinical trial . Fasting blood glucose , HbA1C , and lipids profile were checked before and after the intervention . Data analyses , including parametric and nonparametric tests were done using the SPSS 11.5 software . A p value < 0.05 was regarded as statistically significant . ( RCT registration code : I RCT 2013081114330N1 ) Results : Mean age , BMI , FBG , total cholesterol ( TC ) , triglyceride ( TG ) , LDL , HDL , HbA1c , and sex and had no significant difference at the baseline between the groups . In Nano-curcumin group , a significant decrease was found in HbA1C , FBG , TG , and BMI comparing results of each subject before and after the treatment ( p<0.05 ) . By comparing pre- and post-treatment values among the groups , HbA1c , eAG , LDL-C , and BMI variables showed significant differences ( p<0.05 ) . Conclusion : These findings suggest an HbA1c lowering effect  for Nano-curcumin in type-2 diabetes ; also , it is partially decrease in serum LDL-C and BMI AIM to evaluate the effects of curcumin on total cholesterol , LDL cholesterol , HDL cholesterol , and triglyceride in acute coronary syndrome patients . METHODS this study were conducted at Dr. Cipto Mangunkusumo General Hospital ( RSUPN-CM ) , Persahabatan Hospital , MMC Hospital and Medistra Hospital , Jakarta . The study started from 1 May 2005 to 5 May 2006 . Study Design was an interventional study which was a r and omized double blind controlled trial to evaluate the effects of curcumin administration at escalating doses ( low dose 3 times 15 mg/day , moderate dose 3 times 30 mg/day , and high dose 3 times 60 mg/day ) on total cholesterol level , LDL cholesterol level , HDL cholesterol level , and triglyceride level in ACS patients . RESULTS a 75 ACS patients undergoing r and omization participated in r and omized controlled trial ( RCT ) . Of the 75 ACS patients participating in that RCT , 67 received care at RSCM , 6 at Persahabatan Hospital , and 2 at MMC Hospital . As many as 63 patients were able to participate in the RCT up to its conclusion . There was no significant difference in age , sex , risk factor of dyslipidemia , DM , smoking , hypertension , CHD history in family , height , body weight and body mass index , waist circumference , systolic blood pressure , diastolic blood pressure in the four groups of patients . This showed that the r and omization performed was reasonably good . There was no significant difference in laboratory parameters , such as total cholesterol , LDL cholesterol , HDL cholesterol , and triglyceride , fasting blood glucose , blood glucose 2 hours PP , glyco Hb , triglyceride , Hb , Ht , leukocyte , thrombocyte , ureum , creatinine , SGOT , SGPT , in the four groups . There was no significant difference in types of ACS and locations of ACS in the four groups as well . There was no significant difference in statin medicatios ( simvastatin ) , aspirin ACE inhibitor , and DM medications in the four groups . No patient used  tiazolidindion . No significant difference was found in the percentage of compliance in the four groups of patients . The effects of curcumin on total cholesterol level and LDL cholesterol level , there was a trend that the lower the dose of curcumin , the higher the effect of reduction . For HDL cholesterol level , there was also a trend that the lower the dose of curcumin , the higher the effect of increase in HDL cholesterol level . However , for triglyceride the pattern was not the same , and the group of moderate-dose curcumin shoed the minimal effect of increase , followed by the low-dose curcumin and finally the high-dose curcumin that showed the highest effect of increase . CONCLUSION the administration of low-dose curcumin showed a trend of reduction in total cholesterol level and LDL cholesterol level in ACS patients Curcumin is a phytocompound found in the root of turmeric , a common herbal ingredient in many Asian cuisines . The compound contains anti-inflammatory activity , which is mediated through an up-regulation of adiponectin and reduction of leptin . Consumption of curcumin was shown to prevent some deteriorative conditions caused by inflammation , such as ulcerative colitis , rheumatoid arthritis and esophagitis , and so on . Inflammation-associated cardiovascular conditions such as atherosclerosis are common in diabetes patients . The anti-inflammation effect of curcumin might be beneficial to prevent such condition in these patients . We aim to evaluate an antiatherosclerosis effect of curcumin in diabetes patients . Effects of curcumin on risk factors for atherosclerosis were investigated in a 6-month r and omized , double-blinded and placebo-controlled clinical trial that included subjects diagnosed with type 2 diabetes . An atherosclerosis parameter , the pulse wave velocity , and other metabolic parameters in patients treated with placebo and curcumin were compared . Our results showed that curcumin intervention significantly reduced pulse wave velocity , increased level of serum adiponectin and decreased level of leptin . These results are associated with reduced levels of homeostasis model assessment -insulin resistance , triglyceride , uric acid , visceral fat and total body fat . In summary , a 6-month  curcumin  intervention in type 2 diabetic population lowered the atherogenic risks . In addition , the extract helped to improve relevant metabolic profiles in this high-risk population BACKGROUND Type 2 diabetes ( T2D ) is an established risk factor for cardiovascular disease ( CVD ) and is associated with disturbed metabolism of lipids and lipoproteins . Curcuminoids are natural products with anti-diabetic and lipid-modifying actions but their efficacy in improving dyslipidemia in diabetic individuals has not been sufficiently studied . OBJECTIVE To investigate the efficacy of supplementation with curcuminoids , plus piperine as an absorption enhancer , in improving serum lipids in patients with T2D . METHODS In this 12-week r and omized double-blind placebo-controlled trial , subjects with T2D ( n=118 ) were assigned to curcuminoids ( 1000mg/day plus piperine 10mg/day ) or placebo plus st and ard of care for T2D . Serum concentrations of lipids including total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , high-density lipoprotein cholesterol ( HDL-C ) , triglycerides ( TG ) , lipoprotein(a ) [ Lp(a ) ] , and non-HDL-C were determined at baseline and at the end of trial . RESULTS Between-group comparison of change in the study parameters revealed significant reductions in serum levels of TC ( -21.86±25.78 versus -17.06±41.51 , respectively ; p=0.023 ) , non-HDL-C ( -23.42±25.13 versus -16.84±41.42 , respectively ; p=0.014 ) and Lp(a ) ( -1.50±1.61 versus -0.34±1.73 , respectively ; p=0.001 ) and elevations in serum HDL-C levels ( 1.56±4.25 versus -0.22±4.62 , respectively ; p=0.048 ) in the curcuminoids group as compared with the placebo group ( p<0.05 ) . Serum TG and LDL-C changes did not show any significant difference between the study groups ( p>0.05 ) . CONCLUSION Curcuminoids supplementation can reduce serum levels of atherogenic lipid indices including non-HDL-C and Lp(a ) . Therefore , curcuminoids supplementation could contribute to a reduced risk of cardiovascular events in dyslipidemic patients with T2D Curcumin has a therapeutic potential in treating diabetic kidney disease ( DKD ) while potential mechanisms underlining this beneficial effect remain to be eluci date d. In the present study , curcumin intervention was performed in patients with Type II diabetes mellitus ( T2DM ) by oral intake of curcumin at the dose of 500 mg/day for a period of 15 - 30 days .  Nephritic excretion of urinary micro-albumin ( U-mAlb ) and blood metabolic indexes were assessed before and after this intervention . In addition , the lipid oxidation index , malondialdehyde ( MDA ) in plasma and the status of anti-oxidative Nrf2 system in blood lymphocytes were measured . The effect of curcumin on inflammation was assessed by measuring plasma lipopolysaccharide ( LPS ) content and inflammatory signaling protein in blood lymphocytes . A self-comparison method was used for assessing statistical significance s of these measurements . Here we show that curcumin intervention markedly attenuated U-mAlb excretion without affecting metabolic control of participated patients . In addition , curcumin  reduced plasma MDA level with enhanced the Nrf2 system specifically regulated protein , NAD(P)H quinone oxidoreductase 1 ( NQO-1 ) together with other anti-oxidative enzymes in patients ' blood lymphocytes . Furthermore , we observed reduced plasma LPS content and increased IκB , an inhibitory protein on inflammatory signaling in patient 's lymphocytes after curcumin administration . Finally , several gut bacterials important for maintaining gut barrier integrity and function were upregulated by curcumin . In conclusion , short-term curcumin intervention ablates DKD progress with activating Nrf2 anti-oxidative system and anti-inflammatory efficacies in patients with T2DM SCOPE We previously found that curcuminoids  decreased blood glucose and improved insulin resistance by reducing serum free fatty acids ( FFAs ) and increasing fatty acid oxidation in skeletal muscle of diabetic rats . This study was to investigate whether curcuminoids have beneficial effects on type 2 diabetic patients , and its possible mechanisms . METHODS AND RESULTS Overweight/obese type 2 diabetic patients ( BMI ≥ 24.0 ; fasting blood glucose ≥ 7.0 mmol/L or postpr and ial blood glucose ≥11.1 mmol/L ) were r and omly assigned to curcuminoids ( 300 mg/day ) or placebo for 3 months . Bodyweight , glycosylated hemoglobin A1c ( HbA1c , % ) , serum fasting glucose , FFAs , lipids , and lipoprotein lipase ( LPL ) were determined . A total of 100 patients ( curcuminoids , n = 50 ; placebo , n = 50 ) completed the trial .  Curcuminoids supplementation significantly decreased fasting blood glucose ( p < 0.01 ) , HbA1c ( p = 0.031 ) , and insulin resistance index ( HOMA-IR ) ( p < 0.01 ) in type 2 diabetic patients  . Curcuminoids also led to a significant decrease in serum total FFAs ( p < 0.01 ) , triglycerides ( P = 0.018 ) , an increase in LPL activity ( p < 0.01 ) . CONCLUSION These findings suggest a glucose-lowering effect of curcuminoids in type 2 diabetes , which is partially due to decrease in serum FFAs , which may result from promoting fatty acid oxidation and utilization Dyslipidemia is a leading risk factor for cardiovascular disease and is also a common feature of obesity . Curcumin is a bioactive phytochemical with well-known antioxidant , anti-inflammatory , and cardioprotective properties . The present study investigated the hypolipidemic activity of curcumin in obese individuals . Participants ( n = 30 ) were treated with curcuminoids ( 1 g/day ) , or placebo in a r and omized , double-blind , placebo-controlled , crossover trial . Serum concentrations of total cholesterol , triglycerides , low-density lipoprotein cholesterol and high-density lipoprotein cholesterol , together with anthropometric parameters and high-sensitivity C-reactive protein were measured before and after each treatment period . Anthropometric parameters including weight , BMI , waist circumference , hip circumference , arm circumference , and body fat remained statistically unchanged by the end of trial ( p > 0.05 ) . As for the lipid profile parameters , serum triglycerides were significantly reduced following curcumin supplementation ( p = 0.009 ) . However , curcuminoids were not found to affect serum levels of total cholesterol , low-density lipoprotein cholesterol , high-density lipoprotein cholesterol , and high-sensitivity C-reactive protein ( p > 0.05 ) . In summary , the findings of the present study indicated that curcuminoid supplementation ( 1 g/day for 30 days ) leads to a significant reduction in serum triglycerides concentrations but do not have a significant influence on other lipid profile parameters as well as body mass index and body fat Numerous interventional studies in clinical and pre clinical setting stated that intake of curcumin may provide protection against cardiovascular disease . The aim of this trial was investigation of curcumin efficiency on some cardiovascular risk factors in patients with coronary artery disease ( CAD ) . A total of 33 patients with CAD who fulfilled inclusion and exclusion criteria were entered the study . Patients were r and omly assigned to receive curcumin or placebo , 500 mg capsules , four times daily for 8 weeks . Lipid profile , blood glucose and high sensitive C-reactive protein ( hs-CRP ) levels were analyzed at baseline and two months after treatment . Serum levels of triglycerides ( P=0.01 ) , LDL-cholesterol ( P=0.03 ) and VLDL-cholesterol ( P=0.04 ) significantly decreased in the curcumin group compared to baseline , without significant changes in total cholesterol , HDL-cholesterol , blood glucose and hs-CRP levels . In all mentioned laboratory parameters , significant difference was not detected between curcumin and placebo . Although curcumin improved some of lipid profile components , it did not show appreciable effect on inflammatory markers in patients with CAD . Therefore , more detailed assessment of metabolic effects or anti-inflammatory activities of curcumin need to perform by extensive human study Studies in animals and a short-term human study have suggested that curcumin , a polyphenolic compound concentrated in the curry spice turmeric , decreases serum cholesterol concentration . However , no controlled human trials have examined the effect of curcumin on cholesterol . This study investigated the effects of consuming curcumin on the  serum lipid profile in men and women . Elderly subjects ( n=36 ) consumed 4 g/d curcumin , 1g/d curcumin , or placebo in a 6-month , r and omized , double-blind trial . Plasma curcumin and its metabolites were measured at 1 month , and the serum lipid profile was measured at baseline , 1 month , and 6 months . The plasma curcumin concentration reached a mean of 490 nmol/L. The  curcumin concentration was greater after capsule than powder administration . Consumption of either dose of curcumin did not significantly affect triacylglycerols , or total , LDL , and HDL cholesterol over 1 month or 6 months . However , the concentrations of plasma curcumin and serum cholesterol were positively and significantly correlated . Curcumin consumption does not appear to have a significant effect on the serum lipid profile , unless the absorbed concentration of curcumin is considered , in which case curcumin may modestly increase cholesterol Background : Nonalcoholic fatty liver disease ( NAFLD ) is one of the most common hepatic diseases in the general adult population . Dyslipidemia , hyperuricemia , and insulin resistance are common risk factors and accompanying features of NAFLD . Curcumin is a dietary natural product with beneficial metabolic effects relevant to the treatment of NAFLD . Aim : To assess the effects of curcumin on metabolic profile in subjects with NAFLD . Methods : Patients diagnosed with NAFLD ( grade s 1–3 ; according to liver sonography ) were r and omly assigned to curcumin ( 1000 mg/d in 2 divided doses ) ( n = 50 ) or control ( n = 52 ) group for a period of 8 weeks . All patients received dietary and lifestyle advises before the start of trial . Anthropometric measurements , lipid profile , glucose , insulin , glycated hemoglobin , and uric acid concentrations were measured at baseline and after 8 weeks of follow-up . Results : Eighty-seven subjects ( n = 44 and 43 in the curcumin and control group , respectively ) completed the trial . Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol ( P < 0.001 ) , low-density lipoprotein cholesterol ( P < 0.001 ) , triglycerides ( P < 0.001 ) , non – high-density lipoprotein cholesterol ( P < 0.001 ) , and uric acid ( P < 0.001 ) , whereas serum levels of high-density lipoprotein cholesterol and glucose control parameters remained unaltered . Curcumin was safe and well tolerated during this study . Conclusion : Results of the present trial suggest that curcumin supplementation reduces serum lipids and uric acid concentrations in patients with NAFLD BACKGROUND Low adiponectin levels are discussed as risk factor for cardiovascular events . This is of special importance in individuals with type 2 diabetes ( T2DM ) because they are at higher risk for cardiovascular diseases . The present study aim ed to investigate the effect of two plant oils rich in polyunsaturated fatty acids ( PUFA ) , with different content of omega-3 fatty acids , on adiponectin levels , glucose and lipid metabolism in T2DM individuals treated either with insulin or oral anti-diabetics ( OAD ) . METHODS Ninety-two subjects with T2DM [ 34 treated with insulin ( T2DM-Ins ) and 58 treated with OAD ( T2DM-OAD ) ] participated in this r and omised , double-blind , parallel intervention study . Individuals received either 9 g of nut oil ( n-3:n-6 ratio : 1.3 : 6.1 ) or mixed oil ( n-3:n-6 ratio : 0.6 : 5.7 ) per day for 10 weeks . The fatty acid profile , tocopherol , adiponectin levels and parameters regarding glucose and lipid metabolism were assessed at baseline , during and after the intervention . RESULTS Compliance was confirmed by significant increases in γ-tocopherol and PUFA in both oil groups . An increase in adiponectin levels in T2DM-Ins participants ( + 6.84 % in nut oil and + 4.47 % in mixed oil group after 10 weeks compared to baseline ) was observed , albeit not significantly different from T2DM-OAD individuals ( P = 0.051 ) . Lipid and glucose metabolism were not affected by the intervention . CONCLUSIONS The present study provides evidence that a small and easy change in dietary behaviour towards better fat quality moderately increases adiponectin levels in T2DM-Ins subjects , independently of the administered plant oil OBJECTIVE The objective of this study was to evaluate and compare the effects of gliclazide-modified release ( gliclazide-MR ) , metformine ( MET ) and pioglitazone ( PIO ) monotherapies on glycemic control and conventional/non-conventional cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus ( T2DM ) . MATERIAL AND METHODS A single center , r and omized , 52-wk comparator-controlled clinical study was carried out in patients with newly diagnosed uncontrolled T2DM . A total of 57 patients were r and omized into gliclazide-MR , metformin and pioglitazone groups . Drugs were administered for 12 months . Anthropometric measurements , fasting plasma glucose ( FPG ) , postpr and ial plasma glucose ( PPG ) , HbA1c , insulin , HOMA-IR , lipid parameters , the markers of coagulation/fibrinolysis , inflammation and endothelial dysfunction were measured at baseline and at months 3 , 6 , and 12 . RESULTS In the gliclazide-MR group , HC , FPG , HbA1c , insulin , HOMA-IR , TC , trigylcerides , Lp ( a ) , E-selectin and Hcy were significantly decreased after treatment compared to baseline . In the MET group , BMI , WC , FPG , PPG , HbA1c , ICAM-1 and Hcy significantly decreased after treatment compared to baseline . In PIO group , WC , HC , FPG , PPG , HbA1c , C-peptid , HOMA-IR , trigylcerides , vWF , IL-6 , ICAM-1 , E-selectin and Hcy significantly decreased after treatment compared to baseline , whereas , HDL-C increased . At the end of the month 12 , the decreases in insulin and HOMA-IR score were more pronounced with PIO compared to gliclazide . CONCLUSIONS Gliclazide-MR , MET and PIO monotherapies , were equally effective in proving glycemic control in patients with newly diagnosed , oral antidiabetic (OAD)-naive T2DM . But , improvements in conventional/non-conventional cardiovascular risk factors were more pronounced in patients on PIO therapy compared to gliclazide and MET therapies . Also , all of the 3 drugs represent effective and safe first-line pharmacological treatment options in these patients High blood glucose level , lipid profile disturbances and plasma homocysteine ( Hcy ) are important risk factors for cardiovascular diseases in patients with type 2 diabetes . This study was conducted to evaluate and compare effects of glimepiride/metformin combination versus gliclazide/metformin combination on cardiovascular risk factors in type-2 diabetes mellitus ( T2DM ) patients . One hundred and eighty T2DM patients were r and omly allocated for treatment with placebo ( control ) , metformin ( 500 mg twice daily ) , glimepiride ( 3 mg once daily ) , gliclazide ( 80 mg once daily ) , metformin plus glimepiride or metformin plus gliclazide for 3 months . We evaluated plasma levels of glucose ( PG ) , glycated hemoglobin ( HbA1C ) , Hcy , vitamin B12 , folic acid and lipid profile before treatment and 3 months post treatment . Compared to metformin treated patients , glimepiride plus metformin induced significant reductions in : fasting plasma glucose , postpr and ial PG level , HbA1C % and Hcy level . Conversely , plasma folic acid and vitamin B12 were significantly increased . The levels of total cholesterol and triglyceride were significantly decreased ; low-density lipoprotein was markedly decreased , whereas high-density lipoprotein was significantly increased and hence risk ratio was signiﬁcantly decreased . Similar results but with lower values were obtained using combination of metformin plus gliclazide on glycemic control only . Combination of glimepiride with metformin was superior to gliclazide plus metformin in alleviating the cardiovascular risk factors in type 2 diabetes mellitus patients Abstract It is known that there is a significant interplay of insulin resistance , oxidative stress , dyslipidemia , and inflammation in type 2 diabetes mellitus ( T2DM ) . The study was undertaken to investigate the effect of turmeric as an adjuvant to anti-diabetic therapy . Sixty diabetic subjects on metformin therapy  were recruited and r and omized into two groups ( 30 each ) . Group I received st and ard metformin treatment while group II was on st and ard metformin therapy with turmeric ( 2 g ) supplements for 4 weeks . The biochemical parameters were assessed at the time of recruitment for study and after 4 weeks of treatment . Turmeric supplementation in metformin treated type 2 diabetic patient significantly decreased fasting glucose ( 95 ± 11.4 mg/dl , P < 0.001 ) and HbA1c levels ( 7.4 ± 0.9 % , P < 0.05 ) . Turmeric administered group showed reduction in lipid peroxidation , MDA ( 0.51 ± 0.11 µmol/l , P < 0.05 ) and enhanced total antioxidant status ( 511 ± 70 µmol/l , P < 0.05 ) . Turmeric also exhibited beneficial effects on dyslipidemia LDL cholesterol ( 113.2 ± 15.3 mg/dl , P < 0.01 ) , non HDL cholesterol ( 138.3 ± 12.1 mg/dl , P < 0.05 ) and LDL/HDL ratio ( 3.01 ± 0.61 , P < 0.01 ) and reduced inflammatory marker , hsCRP ( 3.4 ± 2.0 mg/dl , P < 0.05 ) . Turmeric supplementation as an adjuvant to T2DM on metformin treatment had a beneficial effect on blood glucose , oxidative stress and inflammation BACKGROUND In the present study , the improvement of diabetic microangiopathy and retinopathy was evaluated in 38 diabetic patients treated with a novel curcumin phospholipids delivery form ( Meriva ® ) .  METHODS Diabetes was diagnosed at least 5 years before inclusion and all patients had signs of retinal oedema and of peripheral microangiopathy .  Meriva ® was administered at the dosage of 2 tablets/day ( each tablet containing 500 mg Meriva ® corresponding to 100 mg curcumin ) for a period of at least 4 weeks in addition to the st and ard management plan , while a comparable group of subjects ( n = 39 ) followed the st and ard management plan alone . RESULTS All subjects ( treatment and controls ) completed the follow-up period , there were no dropouts and Meriva ® showed an optimal tolerability . At 4 weeks , microcirculatory and clinical evaluations indicated an improvement of microangiopathy . In terms of peripheral microangiopathy , in the Meriva ® group , there was a significant improvement in the venoarteriolar response ( p<0.05 ) and a decrease in the score of peripheral oedema ( p<0.05 ) , a sign typically associated with the failure of the venoarteriolar response . At the retinal level , high-resolution , duplex scanning , used to measure retinal flow , showed improvements in the Meriva ® treated patients . The evaluation of retinal oedema ( Steigerwalt 's scale ) showed an improvement associated with improved visual acuity ( Snellen scale ) . There were no clinical or microcirculatory effects in controls . CONCLUSION These preliminary observations , indicate the value of curcumin , when administered in a bioavailable form as with Meriva ® , in the management of diabetic microangiopathy and retinopathy OBJECTIVE Previous experimental studies have suggested curcumin as a safe phytochemical that can improve insulin resistance through effects on adiponectin and leptin . This study aim ed to investigate the effect of curcumin on circulating adiponectin and leptin concentrations in patients with metabolic syndrome . METHODS In this pilot , r and omized , double-blind , placebo-controlled trial , subjects who met the criteria of metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III criteria were r and omly assigned to curcumin ( n = 59 ; 1000 mg/d ) or a placebo ( n = 58 ) for 8 wk . Serum adiponectin and leptin concentrations were determined before and after intervention . The pooled effect size for the impact of curcumin supplementation on serum adiponectin and leptin levels was also estimated using r and om-effects meta analysis . RESULTS Eight-week supplementation with curcumin was associated with a significant increase in serum adiponectin levels ( P < 0.001 ) and a reduction in serum leptin concentrations ( P < 0.001 ) . Serum leptin : adiponectin ratio was also improved by curcumin ( P < 0.001 ) . These beneficial effects of curcumin remained significant after adjustment for changes in serum lipids and glucose concentrations and baseline differences in body mass index and serum levels of glucose and glycated hemoglobin as potential confounders of treatment response . Meta analysis suggested that curcumin supplementation can increase adiponectin levels by 76.78 % ( 95 % CI : 6.14 - 147.42 ; P = 0.0330 ) , and reduce leptin by 26.49 % ( 95 % CI : -70.44 to 17.46 ) , however this latter effect size did not reach statistical significance ( P = 0.238 ) . CONCLUSIONS Curcumin can improve serum levels of adiponectin and leptin in patients with metabolic syndrome . This trial was registered at the UMIN Clinical Trials Registry ( http://www.umin.ac.jp/ctr/ ) under Trial No. UMIN000018339
Conclusion Our findings may encourage curcumin supplementation based on its meaningful effect on glycemic control and positive trend on lipid outcomes in prediabetes and T2DM
Scope Studies have demonstrated inconsistent effects of curcumin on glycemic outcomes and lipid parameters in patients with prediabetes and type 2 diabetes mellitus ( T2DM ) .
This study aim ed to assess the effect of curcumin on glycemic control and lipid profile in prediabetes and T2DM .